Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 GlobeNewswire October 27, 2025 NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions […]

Lakeland Financial Reports Third Quarter Performance; Net Income Grows by 13% to $26.4 Million, as Net Interest Income Expands by 14% GlobeNewswire October 27, 2025 WARSAW, Ind., Oct. 27, 2025 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported net income of $26.4 million for the three

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting GlobeNewswire October 27, 2025 KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically

Petal Health and Shoppers Drug Mart Collaborate to Expand Access to Care Across Canada Integration of Petal Health's patient flow solution into Shoppers Drug Mart's pharmacy network will make it easier for Canadians to access timely care from trained pharmacists. GlobeNewswire October 27, 2025 Montréal, Oct. 27, 2025 (GLOBE NEWSWIRE) — Petal Health, a leader

Doubledown Interactive to Report 2025 Third Quarter Results on November 10 and Host Conference Call and Webcast GlobeNewswire October 27, 2025 SEOUL, South Korea, Oct. 27, 2025 (GLOBE NEWSWIRE) — DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company“), a leading developer and publisher of digital games on mobile and web-based platforms, announced today

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 GlobeNewswire October 27, 2025 NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits Neumora plans

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025 GlobeNewswire October 27, 2025 NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and

Immatics Appoints Amie Krause as Chief People Officer GlobeNewswire October 27, 2025 Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective

Chijet Motor Company Announces Closing of $300 Million Private Placement in Cryptocurrency GlobeNewswire October 27, 2025 New York, NY, Oct. 27, 2025 (GLOBE NEWSWIRE) — Chijet Motor Company, Inc. (NASDAQ: CJET) (“Chijet” or the “Company”) today announced the successful closing of a private placement offering of units, consisting of ordinary shares and warrants, for gross

EDAP to Participate in the UBS Global Healthcare Conference GlobeNewswire October 27, 2025 EDAP to Participate in the UBS Global Healthcare Conference Company to Host 1×1 Investor Meetings on Monday, November 10th, 2025 AUSTIN, Texas, October 27, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced